MICHAEL BUSCH: Open Payments
NPI 1235680331 · SAGINAW, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$312 in 14 payments from 9 companies in 2025. Trend: 2023 $1,141 · 2024 $568 · 2025 $312
Food & beverage: $312
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 3 | $75 |
| Astellas Pharma US Inc | 2 | $47 |
| Novo Nordisk Inc | 2 | $43 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $38 |
| Janssen Pharmaceuticals, Inc | 1 | $36 |
| Corcept Therapeutics | 1 | $27 |
| Amgen Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Exact Sciences Corporation | 1 | $14 |
Products named: Veozah, Kerendia, INVEGA SUSTENNA, SHINGRIX, Ozempic, Korlym, BEXSERO, TRELEGY ELLIPTA.
Industry payments across MI — which companies pay providers there.
